TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26965288

Group type: EXPERIMENTAL
Intervention: 9-lipid panel in BALF
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Independent cohort replication
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Leukotoxin levels
Number of subjects: 114
Study: 26965296

Group type: EXPERIMENTAL
Intervention: FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FG-3019
Number of subjects: 0
Study: 26965536

Group type: EXPERIMENTAL
Intervention: High CFR with low IMR (Group A)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: High CFR with high IMR (Group B)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Low CFR with low IMR (Group C)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Low CFR with high IMR (Group D)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Low CFR
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: High IMR with low CFR
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Overt microvascular disease
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Multivessel disease
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Physiological index inclusion
Number of subjects: 313
Study: 26965794

Group type: EXPERIMENTAL
Intervention: Empirical treatment with commonly used antimicrobials as per IDSA guidelines
Number of subjects: 447

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 447
Study: 26965870

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridisation (FISH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nugent scoring
Number of subjects: 120
Study: 26965915

Group type: EXPERIMENTAL
Intervention: Romidepsin 14 mg/m² on days 1, 8, and 15 of six 28-day cycles; maintenance dosing twice per cycle after 12 cycles, and potentially reduced to once per cycle after 24 cycles for those who had received maintenance for ≥6 months.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Romidepsin (continuation of treatment for patients with SD),
Number of subjects: 130
Study: 26966027

Group type: EXPERIMENTAL
Intervention: ASP3026 (oral ALK inhibitor) at doses of 25-800 mg once daily in 28-day cycles
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ASP3026 (oral ALK inhibitor)
Number of subjects: 46
Study: 26966029

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Lemtrada®)
Number of subjects: 15
Study: 26966545

Group type: EXPERIMENTAL
Intervention: e-therapeutic platform (Next.Step) used for 12 weeks in addition to standard intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 80
Study: 26966551

Group type: EXPERIMENTAL
Intervention: CAU plus IBD-specific cognitive-behavioural therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical care-as-usual (CAU)
Number of subjects: 100
Study: 26966573

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusions (RBCTx)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: ESA + IV iron
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Overall antianemic therapy
Number of subjects: 1018
Study: 26967692

Group type: EXPERIMENTAL
Intervention: Complete nephrogenic DI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Primary polydipsia (PP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Complete central DI
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 41
Study: 26967774

Group type: EXPERIMENTAL
Intervention: Standardized analgesia protocol
Number of subjects: 96
Study: 26968374

Group type: EXPERIMENTAL
Intervention: Clinical and laboratory parameters assessed daily for up to 6 days during acute illness and at a follow-up visit 1 week later.
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Patients with confirmed dengue.
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Early virological and serological correlates of severe disease.
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Assessment of the new World Health Organization classification scheme for dengue.
Number of subjects: 8000
Study: 26968534

Group type: EXPERIMENTAL
Intervention: Idelalisib and entospletinib combination therapy
Number of subjects: 0
Study: 26968708

Group type: EXPERIMENTAL
Intervention: EGFR-targeted CAR-T cell infusions
Number of subjects: 11
Study: 26968833

Group type: EXPERIMENTAL
Intervention: Neonatal arterial ischemic stroke (NAIS)
Number of subjects: 80
Study: 26969082

Group type: EXPERIMENTAL
Intervention: Total body irradiation (with or without prior central nervous system irradiation)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Transplanted patients who never received any irradiation
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Transplanted without total body irradiation who received central nervous system irradiation
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Patients irradiated or transplanted at older than 10 years of age
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Thyroid malignancy
Number of subjects: 588
Study: 26969258

Group type: EXPERIMENTAL
Intervention: Isavuconazole 200 mg three times daily for six doses, followed by 200 mg/day until resolution, failure, or for 180 days; median treatment duration was 84 days (IQR 19-179, range 2-882).
Number of subjects: 37

Group type: COMPARATOR
Intervention: Isavuconazole (primary treatment)
Number of subjects: 37
Study: 26969509

Group type: EXPERIMENTAL
Intervention: Flemish CARES tool
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Initial patient survey
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Second survey after 1 week
Number of subjects: 150
Study: 26970381

Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and MMF
Number of subjects: 86

Group type: COMPARATOR
Intervention: ATG, tacrolimus, and methotrexate or MMF
Number of subjects: 86
Study: 26970832

Group type: EXPERIMENTAL
Intervention: Higher relaxin-2 levels soon after delivery
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Higher sFlt1 levels
Number of subjects: 98
Study: 26970970

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 45
Study: 26971081

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sertraline 300 mg/day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sertraline 400 mg/day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sertraline (any dose)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Sertraline 100-200 mg/day
Number of subjects: 172
Study: 26971192

Group type: EXPERIMENTAL
Intervention: Drug taper
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Tapering to no medications
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Trials requiring treatment resistance
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: History of suicidal ideation or behaviour
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Overall research participation
Number of subjects: 540
Study: 26971488

Group type: EXPERIMENTAL
Intervention: EEG background pattern at 24h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG background pattern within 12h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive values of EEG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactivity parameters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment of electrographic status epilepticus
Number of subjects: 0
Study: 26971680

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of autologous bone marrow-derived mesenchymal stromal cells (MSCs) at a median dose of 1.2 × 10(6) MSCs/kg body weight, with 2-3 injections per patient.
Number of subjects: 9
Study: 26971692

Group type: EXPERIMENTAL
Intervention: Vitamin D3 therapy
Number of subjects: 0
Study: 26972567

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived endothelial progenitor cells (EPC), administered through the hepatic artery in a single administration.
Number of subjects: 12
Study: 26973142

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels at admittance
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Follow-up assessment after 6 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Higher baseline CRP levels
Number of subjects: 124
Study: 26973324

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 246
Study: 26973445

Group type: EXPERIMENTAL
Intervention: Combined cognitive and physical intervention scheme (LLM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active control group (AC)
Number of subjects: 50
Study: 26973538

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing to identify genetic mutations.
Number of subjects: 0
Study: 26973791

Group type: EXPERIMENTAL
Intervention: Iron dextran (Infufer®)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Iron sucrose (Venofer®)
Number of subjects: 143
Study: 26973849

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Perenterol forte 250 mg capsules, twice per day for 7 days after antibiotic discontinuation)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo (matching placebo, twice per day for 7 days after antibiotic discontinuation)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 26974332

Group type: EXPERIMENTAL
Intervention: GOLD quadrants C+D
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: mMRC score ≥2
Number of subjects: 136

Group type: COMPARATOR
Intervention: mMRC, CAT, CCQ questionnaires
Number of subjects: 136
Study: 26974430

Group type: EXPERIMENTAL
Intervention: Group drumming intervention for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-music control group
Number of subjects: 0
Study: 26974526

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg q24h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg q12h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metformin alone (Period 1)
Number of subjects: 30
Study: 26974547

Group type: COMPARATOR
Intervention: Physical activity levels (measured by daily step counts using accelerometry)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical activity levels in ICU survivors with preexisting chronic disease
Number of subjects: 30

Group type: COMPARATOR
Intervention: Health-related quality of life (measured by the 36-item short-form health survey)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frailty (measured by Clinical Frailty Score)
Number of subjects: 30
Study: 26975189

Group type: EXPERIMENTAL
Intervention: dHER2 immunotherapeutic
Number of subjects: 40
Study: 26975937

Group type: EXPERIMENTAL
Intervention: Oral mixed-meal tolerance test (OMTT)
Number of subjects: 240
Study: 26976424

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg intravenously once per week
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Temsirolimus 75 mg intravenously once per week
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg and 75 mg cohorts
Number of subjects: 37
Study: 26976799

Group type: EXPERIMENTAL
Intervention: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (with ribavirin for genotype 1a patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (without ribavirin for genotype 1b patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ribavirin therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 20
Study: 26976872

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 94

Group type: COMPARATOR
Intervention: Echinocandins/L-AmB-based regimen
Number of subjects: 94
Study: 26976960

Group type: EXPERIMENTAL
Intervention: Surgical safety checklists implemented in pediatric surgery
Number of subjects: 28772

Group type: COMPARATOR
Intervention: Pre-checklist group
Number of subjects: 28772

Group type: COMPARATOR
Intervention: Post-checklist group
Number of subjects: 28772
Study: 26977746

Group type: EXPERIMENTAL
Intervention: Nucleoside-Sparing Regimens with Raltegravir and a Boosted Protease Inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26978384

Group type: EXPERIMENTAL
Intervention: Maternal blood lead level (BLL) > 50 µg/L
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Children's blood lead level (BLL) > 50 µg/L
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Maternal BLL associated with offspring's consumption of piped water and animals killed by ammunition
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Children's BLL associated with presence of paint chips in the house and consumption of animals killed by ammunition
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Children's BLL highly associated with maternal BLL on multivariate analyses
Number of subjects: 910
Study: 26978775

Group type: EXPERIMENTAL
Intervention: Disposable intranasal mucosal atomization device (DIMAD)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard reusable nasal atomizer (CRNA)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Patients' satisfaction with DIMAD
Number of subjects: 252
Study: 26979084

Group type: EXPERIMENTAL
Intervention: Intense exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26980207

Group type: EXPERIMENTAL
Intervention: Baseline assessments using a standardized battery of functional brain imaging, structural brain imaging, and behavioral probes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3 months after baseline.
Number of subjects: 0
Study: 26980473

Group type: EXPERIMENTAL
Intervention: Icotinib (250 mg, three times daily)
Number of subjects: 54
Study: 26980480

Group type: EXPERIMENTAL
Intervention: PepCan 50 μg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PepCan 100 μg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PepCan overall
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PepCan
Number of subjects: 31
Study: 26981247

Group type: EXPERIMENTAL
Intervention: ONCOS-102 plus daily low-dose oral cyclophosphamide (CPO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ONCOS-102
Number of subjects: 12
Study: 26981283

Group type: EXPERIMENTAL
Intervention: Computer-assisted home exercise program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Printed instructions for home exercises
Number of subjects: 57
Study: 26982008

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 293
Study: 26982511

Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy
Number of subjects: 66
Study: 26983018

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 0
Study: 26983912

Group type: EXPERIMENTAL
Intervention: Pazopanib plus CapeOx (capecitabine and oxaliplatin)
Number of subjects: 66
Study: 26984361

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1450
Study: 26984445

Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg) administered intravenously every 21 days for 3 cycles
Number of subjects: 66

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg orally) as a positive control
Number of subjects: 66
Study: 26984642

Group type: EXPERIMENTAL
Intervention: cobas KRAS mutation test
Number of subjects: 461

Group type: COMPARATOR
Intervention: therascreen KRAS RGQ PCR kit test
Number of subjects: 461
Study: 26985232

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum bv. infantis CCUG 52,486 combined with gluco-oligosaccharide (B. longum + Gl-OS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26986777

Group type: EXPERIMENTAL
Intervention: Selective block of the four principal nerves in the arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26987488

Group type: EXPERIMENTAL
Intervention: Rivaroxaban administered within 30 days of the index stroke for secondary prevention of stroke
Number of subjects: 2000
Study: 26987662

Group type: EXPERIMENTAL
Intervention: Shared control using BMI and robotic assistance
Number of subjects: 2

Group type: COMPARATOR
Intervention: BMI control alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Shared control
Number of subjects: 2
Study: 26988350

Group type: EXPERIMENTAL
Intervention: Ambulance presentation
Number of subjects: 1068
Study: 26988379

Group type: EXPERIMENTAL
Intervention: Prolonged VF detection (30/40 intervals)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Standard VF detection (18/24 intervals)
Number of subjects: 705
Study: 26989059

Group type: EXPERIMENTAL
Intervention: Omega loop gastric bypass
Number of subjects: 46
Study: 26989103

Group type: EXPERIMENTAL
Intervention: COPD patients with ACOS
Number of subjects: 0

Group type: COMPARATOR
Intervention: COPD patients without ACOS
Number of subjects: 0
Study: 26990515

Group type: EXPERIMENTAL
Intervention: Linox ICD leads
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: Linox(smart) ICD leads
Number of subjects: 3840

Group type: COMPARATOR
Intervention: Linox and Linox(smart) ICD leads
Number of subjects: 3840
Study: 26990620

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies measured every trimester and postpartum; IgG aPL levels significantly lower during the second and third trimesters compared to initial screening.
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies measured every trimester and postpartum; IgM aPL titers were negative in the majority of patients and decreased modestly during pregnancy.
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies measured every trimester and postpartum; changes in aPL levels or aPL status.
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LAC) presence.
Number of subjects: 152
Study: 26990995

Group type: EXPERIMENTAL
Intervention: Stable therapy (specifics not provided)
Number of subjects: 2788

Group type: EXPERIMENTAL
Intervention: Pain measurement
Number of subjects: 2788

Group type: EXPERIMENTAL
Intervention: Fatigue measurement
Number of subjects: 2788

Group type: EXPERIMENTAL
Intervention: Function measurement
Number of subjects: 2788
Study: 26991245

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), n=23
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA), n=22
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), n=25
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study: 26991631

Group type: EXPERIMENTAL
Intervention: Higher frailty scores
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Higher comorbidity scores
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Any disability
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Impaired grip strength
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Timed chair stand tests
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Incorporation of frailty scores
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Incorporation of comorbidity scores
Number of subjects: 445
Study: 26991823

Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg once daily (3 weeks on/1 week off)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg once daily (3 weeks on/1 week off)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg plus letrozole 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg
Number of subjects: 12
Study: 26991902

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (60-180 μg)
Number of subjects: 2630
Study: 26992304

Group type: EXPERIMENTAL
Intervention: Radiofrequency segmental thermal ablation of refluxing GSVs
Number of subjects: 93
Study: 26992693

Group type: EXPERIMENTAL
Intervention: Genital epithelial disruptions
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Abnormal vaginal discharge
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Genital signs and symptoms
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Genital ulcers/sores
Number of subjects: 1485
Study: 26993068

Group type: EXPERIMENTAL
Intervention: scFEM depot
Number of subjects: 25

Group type: COMPARATOR
Intervention: scABD depot
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both scABD and scFEM depots
Number of subjects: 25
Study: 26993070

Group type: EXPERIMENTAL
Intervention: Acute hypoglycemia (2.8 mmol/L) during a hyperinsulinemic euglycemic-hypoglycemic glucose clamp after an overnight fast.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy control subjects (n = 7) during acute hypoglycemia (2.8 mmol/L).
Number of subjects: 21

Group type: COMPARATOR
Intervention: Patients with normal awareness of hypoglycemia (NAH) during acute hypoglycemia (2.8 mmol/L).
Number of subjects: 21
Study: 26993071

Group type: EXPERIMENTAL
Intervention: Model-based method to estimate hepatic and extrahepatic insulin clearance
Number of subjects: 100
Study: 26993131

Group type: EXPERIMENTAL
Intervention: dHER2 immunotherapeutic (20, 100, 500 µg) combined with AS15
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: dHER2 immunotherapeutic (500 µg) with the most intense immunization schedule
Number of subjects: 61
Study: 26993266

Group type: EXPERIMENTAL
Intervention: Agalsidase β (1 mg/kg every 2 weeks)
Number of subjects: 1044
Study: 26993370

Group type: EXPERIMENTAL
Intervention: Right-lung bronchoalveolar lavage (BAL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Left-lung bronchoalveolar lavage (BAL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bilateral BAL cultures
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Simulated prescribing based on right or left cultures
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Presence of a radiographic infiltrate in the sampling area
Number of subjects: 79
Study: 26993674

Group type: EXPERIMENTAL
Intervention: Endovenous cyanoacrylate (CA) embolization
Number of subjects: 70
Study: 26993758

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 52